Lipocine (NASDAQ:LPCN – Get Free Report) is projected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.26) per share and revenue of $2.61 million for the quarter.
Lipocine Stock Performance
Shares of NASDAQ:LPCN opened at $3.07 on Wednesday. The company has a 50 day moving average price of $4.19 and a two-hundred day moving average price of $4.56. The company has a market capitalization of $16.42 million, a PE ratio of -4.04 and a beta of 1.23. Lipocine has a 52 week low of $2.91 and a 52 week high of $11.79.
Analysts Set New Price Targets
Separately, StockNews.com assumed coverage on shares of Lipocine in a research report on Wednesday, February 26th. They issued a “hold” rating for the company.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Featured Articles
- Five stocks we like better than Lipocine
- Following Congress Stock Trades
- GitLab: Get In While It’s Down—Big Rebound Ahead
- Conference Calls and Individual Investors
- Tesla Stock: Finding a Bottom May Take Time
- 3 Best Fintech Stocks for a Portfolio Boost
- Duolingo: This Beaten-Down Stock Is About to Rally 38%
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
